氟伐他汀联合阿罗洛尔治疗冠心病心力衰竭的疗效观察

Clinical observation of fluvastatin combined with arotinolol in treatment of coronary heart disease patients with heart failure

目的研究氟伐他汀联合阿罗洛尔治疗冠心病心力衰竭的临床疗效。方法选取2013年2月—2015年1月石家庄市第三医院心内科收治的冠心病心力衰竭患者134例,随机分为对照组和治疗组,每组67例。对照组口服盐酸阿罗洛尔片,10 mg/次,2次/d。治疗组口服氟伐他汀钠缓释片,40 mg/次,1次/d,盐酸阿罗洛尔片的用法用量同对照组。两组患者均连续治疗90 d。观察两组的临床疗效,同时比较两组治疗前后左心室射血分数(LEVF)、左室舒张末期内径(LVDd)、舒张期室间隔厚度(d IVST)、平均动脉压(MAP)、心脏指数(CI)、每搏输出量(SV)、每搏指数(SI)、肺动脉楔压(PAWP)、心率(HR)、体循环阻力(SVR)、肺循环阻力(PVR)的变化。结果治疗后,对照组和治疗组总有效率分别为74.63%、92.54%,两组总有效率比较差异具有统计学意义(P<0.05)。治疗后,两组患者LVEF、MAP、SV、SI均较治疗前显著升高,d IVST、HR、SVR显著降低,同组治疗前后差异有统计学意义(P<0.05),且治疗组这些观察指标的改善程度优于对照组,两组比较差异有统计学意义(P<0.05)。结论氟伐他汀联合阿罗洛尔治疗冠心病心力衰竭具有较好的临床疗效,可改善患者心功能相关指标,且无明显不良反应,值得临床推广应用。

Objective To observe the clinical effect of fluvastatin combined with arotinolol in treatment of coronary heart disease patients with heart failure. Methods Coronary heart disease patients （134 cases） with heart failure in Shijiazhuang the Third Hospital from February 2013 to January 2015 were randomly divided into control and treatment groups, and each group had 67 cases. The patients in the control group werepo administered with Arotinolol Hydrochloride Tablets, 10 mg/time, twice daily. The patients in treatment group werepo administered with Fluvastatin Sodium Extended Release Tablets, 40 mg/time, once daily, and the usage and dosage of Arotinolol Hydrochloride Tablets were the same as control group. Two groups were treated for 90 d. After treatment, the efficacy was evaluated, and the changes of LEVF, LVDd, dIVST, MAP, CI, SV, SI, PAWP, HR, SVR, and PVR in two groups before and after treatment were compared. Results The efficacies in the control and treatment groups were 74.63% and 92.54%, respectively, and there were differences between two groups （P 〈 0.05）. After treatment, LVEF, MAP, SV, and SI in two groups were significantly increased, while dlVST, HR, and SVR were significantly reduced, and the difference was statistically significant in the same group （P 〈 0.05）. And these indicators in treatment group improved better than those in the control group, with significant difference between two groups （P 〈 0.05）. Conclusion Fluvastatin combined with arotinolol has the good clinical effect in treatment of coronary heart disease patients with heart failure, and can improve cardiac function related parameters with less adverse reactions, which is worth clinical promotion.